RNA binding motif protein Y-linked family 2 member E, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RBMY2EP profile across patient tissues and cancer cell-line models. RBMY2EP expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RBMY2EP is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, RBMY2EP RNA expression shows 3,730 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, LIHC, and TGCT as cancer lineages where RBMY2EP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMY2EP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMY2EP survival associations across molecular data types. RBMY2EP RNA expression shows survival associations in the most cancer types (5), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMY2EP RNA expression–survival associations across cancer types. High RBMY2EP expression shows unfavorable associations in LUAD, UCEC, GBM and SKCM, but favorable associations in BLCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for RBMY2EP RNA expression.
This table summarizes RBMY2EP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RBMY2EP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMY2EP shows higher tumor expression in LIHC. The LIHC box plot shows higher RBMY2EP RNA expression in tumor versus normal tissue (log2 FC = +0.026, t-test p = .047).
This table shows molecular features associated with RBMY2EP in patient tissues and cancer cell lines. In patient samples, RBMY2EP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RBMY2EP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
